Frailty, HIV Infection, and Mortality in an Aging Cohort of Injection Drug Users

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Piggott, Damani A ^a,b   Muzaale, Abimereki D ^a,b   Mehta, Shruti H ^b   Brown, Todd T ^a,b   Patel, Kushang V ^c   Leng, Sean X ^a   Kirk, Gregory D ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DEPRESSION; FEMALE; FRAIL ELDERLY; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE;

ADULT; AGED; AGING; BEHAVIOR; COHORT STUDIES; FEMALE; FRAIL ELDERLY; HIV INFECTIONS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84873100763     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054910     Document Type: Article

References (52)

1. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G, (2004) Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 59: 255-263.
2. Xue QL, (2011) The frailty syndrome: definition and natural history. Clin Geriatr Med 27: 1-15.
3. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, et al. (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56: M146-156.
4. Bandeen-Roche K, Xue QL, Ferrucci L, Walston J, Guralnik JM, et al. (2006) Phenotype of frailty: characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci 61: 262-266.
5. High KP, Brennan-Ing M, Clifford DB, Cohen MH, Currier J, et al. (2012) HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 60Suppl 1: S1-18.
6. Mills EJ, Barnighausen T, Negin J, (2012) HIV and aging-preparing for the challenges ahead. N Engl J Med 366: 1270-1273.
7. Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, et al. (2009) Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 49: 1570-1578.
8. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, et al. (2007) Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146: 87-95.
9. Armstrong GL, (2007) Injection drug users in the United States, 1979-2002: an aging population. Arch Intern Med 167: 166-173.
10. Wolfe D, Carrieri MP, Shepard D, (2010) Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 376: 355-366.
11. Degenhardt L, Hall W, Warner-Smith M, (2006) Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 82Suppl 3: iii56-63.
12. Kohli R, Lo Y, Howard AA, Buono D, Floris-Moore M, et al. (2005) Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 41: 864-872.
13. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, et al. (2007) HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 62: 1279-1286.
14. Terzian AS, Holman S, Nathwani N, Robison E, Weber K, et al. (2009) Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. J Womens Health (Larchmt) 18: 1965-1974.
15. Onen NF, Agbebi A, Shacham E, Stamm KE, Onen AR, et al. (2009) Frailty among HIV-infected persons in an urban outpatient care setting. J Infect 59: 346-352.
16. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, et al. (1991) The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 109: 75-100.
17. Salter ML, Lau B, Go VF, Mehta SH, Kirk GD, (2011) HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clin Infect Dis 53: 1256-1264.
18. Saunders JB, Aasland OG, Babor TF, de la FuenteJR, Grant M, (1993) Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 88: 791-804.
19. Weissman MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ, (1977) Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 106: 203-214.
20. Skinner HA, (1982) The drug abuse screening test. Addict Behav 7: 363-371.
21. Mehta SH, Kirk GD, Astemborski J, Galai N, Celentano DD, (2010) Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008. Clin Infect Dis 50: 1664-1671.
22. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, et al. (2011) A Frailty-Related Phenotype Before HAART Initiation as an Independent Risk Factor for AIDS or Death After HAART Among HIV-Infected Men. J Gerontol A Biol Sci Med Sci.
23. Rabe-Hesketh S, Skrondal A (2008) Multilevel and Longitudinal Modeling Using Stata. College Station, TX: Stata Press.
24. Deeks SG, (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62: 141-155.
25. Yao X, Li H, Leng SX, (2011) Inflammation and immune system alterations in frailty. Clin Geriatr Med 27: 79-87.
26. Leng SX, Xue QL, Tian J, Walston JD, Fried LP, (2007) Inflammation and frailty in older women. J Am Geriatr Soc 55: 864-871.
27. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, et al. (2002) Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med 162: 2333-2341.
28. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, et al. (1998) Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280: 1497-1503.
29. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337: 725-733.
30. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, et al. (2001) Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135: 17-26.
31. Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, et al. (2005) Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 161: 999-1012.
32. Wood E, Hogg RS, Lima VD, Kerr T, Yip B, et al. (2008) Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 300: 550-554.
33. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
34. Giordano TP, Gifford AL, White AC Jr, Suarez-Almazor ME, Rabeneck L, et al. (2007) Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 44: 1493-1499.
35. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ, (2011) The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 52: 793-800.
36. Wood E, Hogg RS, Harrigan PR, Montaner JS, (2005) When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis 5: 407-414.
37. Nijhawan A, Kim S, Rich JD, (2008) Management of HIV infection in patients with substance use problems. Curr Infect Dis Rep 10: 432-438.
38. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, et al. (2002) Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 17: 377-381.
39. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, et al. (1998) Self-reported antiretroviral therapy in injection drug users. JAMA 280: 544-546.
40. Kavasery R, Galai N, Astemborski J, Lucas GM, Celentano DD, et al. (2009) Nonstructured treatment interruptions among injection drug users in Baltimore, MD. J Acquir Immune Defic Syndr 50: 360-366.
41. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, et al. (2010) HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 375: 1014-1028.
42. Rockwood K, Song X, Mitnitski A, (2011) Changes in relative fitness and frailty across the adult lifespan: evidence from the Canadian National Population Health Survey. CMAJ 183: E487-494.
43. Khosla N, Juon HS, Kirk GD, Astemborski J, Mehta SH, (2011) Correlates of non-medical prescription drug use among a cohort of injection drug users in Baltimore City. Addict Behav 36: 1282-1287.
44. Szanton SL, Seplaki CL, Thorpe RJ Jr, Allen JK, Fried LP, (2010) Socioeconomic status is associated with frailty: the Women's Health and Aging Studies. J Epidemiol Community Health 64: 63-67.
45. Carroll JE, Cohen S, Marsland AL (2011) Early childhood socioeconomic status is associated with circulating interleukin-6 among mid-life adults. Brain Behav Immun.
46. Nazmi A, Victora CG, (2007) Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health 7: 212.
47. Koster A, Bosma H, Penninx BW, Newman AB, Harris TB, et al. (2006) Association of inflammatory markers with socioeconomic status. J Gerontol A Biol Sci Med Sci 61: 284-290.
48. Joseph C, Kenny AM, Taxel P, Lorenzo JA, Duque G, et al. (2005) Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk. Mol Aspects Med 26: 181-201.
49. Singh T, Newman AB, (2011) Inflammatory markers in population studies of aging. Ageing Res Rev 10: 319-329.
50. Rodriguez-Manas L, Feart C, Mann G, Vina J, Chatterji S, et al. (2012) Searching for an Operational Definition of Frailty: A Delphi Method Based Consensus Statement. The Frailty Operative Definition-Consensus Conference Project. J Gerontol A Biol Sci Med Sci.
51. Ensrud KE, Ewing SK, Taylor BC, Fink HA, Cawthon PM, et al. (2008) Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med 168: 382-389.
52. Crystal S, Akincigil A, Sambamoorthi U, Wenger N, Fleishman JA, et al. (2003) The diverse older HIV-positive population: a national profile of economic circumstances, social support, and quality of life. J Acquir Immune Defic Syndr 33Suppl 2: S76-83.